Show simple item record

dc.contributor.authorMancheño-Corvo, Pablo
dc.contributor.authorLopez-Santalla, Mercedes
dc.contributor.authorMenta, Ramon
dc.contributor.authorDelaRosa, Olga
dc.contributor.authorMulero, Francisca 
dc.contributor.authorDel Rio, Borja
dc.contributor.authorRamirez, Cristina
dc.contributor.authorBüscher, Dirk
dc.contributor.authorBueren, Juan A
dc.contributor.authorLopez-Belmonte, Juan
dc.contributor.authorDalemans, Wilfried
dc.contributor.authorGarin, Marina I
dc.contributor.authorLombardo, Eleuterio
dc.identifier.citationFront Immunol. 2017;8:462.es_ES
dc.description.abstractMesenchymal stem cells (MSCs) are multipotent stromal cells with immunomodulatory properties. They have emerged as a very promising treatment for autoimmunity and inflammatory diseases such as rheumatoid arthritis. Previous studies have demonstrated that MSCs, administered systemically, migrate to lymphoid tissues associated with the inflammatory site where functional MSC-induced immune cells with a regulatory phenotype were increased mediating the immunomodulatory effects of MSCs. These results suggest that homing of MSCs to the lymphatic system plays an important role in the mechanism of action of MSCs in vivo. Thus, we hypothesized that direct intralymphatic (IL) (also referred as intranodal) administration of MSCs could be an alternative and effective route of administration for MSC-based therapy. Here, we report the feasibility and efficacy of the IL administration of human expanded adipose mesenchymal stem cells (eASCs) in a mouse model of collagen-induced arthritis (CIA). IL administration of eASCs attenuated the severity and progression of arthritis, reduced bone destruction and increased the levels of regulatory T cells (CD25+Foxp3+CD4+ cells) and Tr1 cells (IL10+CD4+), in spleen and draining lymph nodes. Taken together, these results indicate that IL administration of eASCs is very effective in modulating established CIA and may represent an alternative treatment modality for cell therapy with eASCs.es_ES
dc.description.sponsorshipThis project has received funding from the Spanish Ministerio de Economía y Competitividad and Comunidad Autónoma de Madrid to TiGenix and the European Union’s Seventh Programme for research, technological development and demonstration under grant agreement No 279174 to TiGenix, CIEMAT, and Farma-Cros.es_ES
dc.publisherFrontiers Mediaes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.subjectadipose mesenchymal stem cellses_ES
dc.subjectcollagen-induced arthritises_ES
dc.subjectintralymphatic routees_ES
dc.subject.meshAdipose Tissue es_ES
dc.subject.meshSelf Efficacy es_ES
dc.subject.meshEpithelial-Mesenchymal Transition es_ES
dc.subject.meshArthritis es_ES
dc.subject.meshImmunomodulation es_ES
dc.titleIntralymphatic Administration of Adipose Mesenchymal Stem Cells Reduces the Severity of Collagen-Induced Experimental Arthritises_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderMinisterio de Ciencia y Competitividad (España)es_ES
dc.contributor.funderComunidad de Madrides_ES
dc.contributor.funder7º Programa Marco - Comisión Europeaes_ES
dc.relation.publisherversion 10.3389/fimmu.2017.00462.es_ES
dc.identifier.journalFrontiers in immunologyes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad de Imagen Moleculares_ES

Files in this item

Acceso Abierto
Acceso Abierto
Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional